Back to search

Aristotle University Of Thessaloniki (AUTH)

Η επίδραση της bevacizumab στην επούλωση των αναστομώσεων του παχέος εντέρου: πειραματική μελέτη σε επίμυες

Abstract

dc:description

The angiogenesis plays an important role in both wound healing and metastatic invasion and spread of malignant cells by supplying the cells with the required nutrients and oxygen. The VEGF (Vascular Endothelial Growth Factor) has a significant value in the angiogenesis process in normal conditions such as in wound healing, as well as in malignant diseases. The levels of VEGF have been found particularly high in the vast majority of malignant tumors including colorectal cancer; this is in relation with the increased metastatic capability of the tumor and with poorer prognosis. Therefore, inhibition of angiogenesis could limit the extent of the malignant development by restricting the growth and metastasis of tumor cells. Bevacizumab is a recombinant humanized monoclonal antibody (IgG1) that binds VEGF-A, forming a complex molecule, and inhibits binding of VEGF-A with VEGF tyrosine kinase receptors (VEGFRs), resulting in blockage of VEGF-mediated signaling pathways leading to angiogenesis. The antiangiogenetic agent bevacizumab is used with increasing frequency in the management of advanced colorectal cancer and in other malignancies; however, taking in view any concern of negative effect on wound healing, it is not well defined which is the actual time for its use from operation. Despite the recommendations and current clinical practice, there has not been any evidence based optimal time for its safe use. This initiative experimental study in rats was designed to investigate the effect of angiogenesis inhibitor bevacizumab on colon anastomotic healing by assessing some specific factors implicated in wound healing process, highlighting ultimately the degree of healing capability. Forty Wistar rats were used. All animals received premedication with light ether and were anaesthetized with intraperitoneal injection of ketamine at dose 40 mg per Kg BW. Under aseptic conditions the surgeon performed a laparotomy by midline incision (average length of 4-5 cm), controlled the peritoneal cavity, found the colon; then resection a part of it and an end-to-end anastomosis in one layer with interrupted sutures with atraumatic Prolene 6-0. The closure of the abdominal wound was achieved in two layers with continuous Prolene 2-0. It was followed by recovery and monitoring of the animals. The rats were randomly divided into four groups of 10 animals each. The A and B groups were the study groups. In these groups, after the performance of anastomosis and before the closure of the abdomen, a solution of the substance bevacizumab (Avastin, Roche Pharma AG, Grenzach-Wyhlen, Germany) in a single dose of 5 mg/kg of body weight was administered intraperitoneally. The C and D groups were the control groups. In these groups instead of the above mentioned bevacizumab solution, only normal saline in equal amount was administered intraperitoneally. All animals recovered well, gained weight and remained healthy throughout the experiment. No bleeding events were noted in any case. Group A and Group C animals were sacrificed on the 7th postoperative day, whereas those of Group B and Group D were sacrificed on the 14th postoperative day. Upon sacrifice, inspection and recording of wound healing score and reopening of the midline incision was performed, followed by careful inspection of the peritoneal cavity for adhesions or collections particularly in the anastomotic area. Following a resection of a 5 cm segment of the colon including the anastomosis was performed and prepared appropriately for bursting pressure measurement; after ligation of the one end and connection of the other end with mercury manometer dipping into water. After that, one-third of the anastomosis tissue was fixed in 10 % formalin solution and sent for histological examination. The rest of the anastomosis tissue placed in sterile Eppendorf tubes and were stored at -70°C. By paracentesis 3-5 cc of blood from Inferior Vena Cava was taken for assessing the studied parameters. A part of the skin from the abdominal wound was resected for histological examination and tissue hydroxyproline assessment; finally euthanasia follows. Deeply frozen anastomoses tissues were homogenized and processed for the assays according to manufacturer instructions of the relevant kits. The biochemical measurements included VEGF, endothelin- 1 (ET-1), C-reactive protein (CRP), prooxidant - antioxidant balance (PAB), carbonylated proteins and hydroxyproline. Histological sections of anastomoses and skin tissues were prepared from paraffin blocks and staining with haematoxylin - eosin. Light microscopy identified the presence of epithelial cells (epithelialization), fibroblasts, collagen and granular tissue. For statistical analysis the Mann Whitney U test was used (s.s. when p<0.05). Hydroxyproline is useful for routine measurement of collagen content in tissue specimens extracts; the presence of it, on 14th day was higher than on 7th day in both control and study groups as expected, but without statistical significance (s.s.). Likewise, it did not differ s.s. between Avastin and Placebo groups. Bevacizumab did not influence anastomotic tissue hydroxyproline level and subsequently the collagen concentrations. The integrity of anastomosis in all cases, in combination with no s.s. differences in histopathological examination (inflammation, fibroblasts, collagen, fibrosis) score or adhesion score, indicate adequate healing capability in all experimental animals, which were not finally affected by bevacizumab administration. However, the bursting strength is the most relevant clinical parameter. The use of Avastin had no substantial effect on anastomotic strength, since the bursting pressure was lower in Avastin groups compared with Placebo groups both on 7th and 14th postoperative days, without statistical significance. VEGF was found increased in Avastin group with s.s. on 7th day, but inactive, when compared with placebo group on 7th day (p=0.010). Also, in control group without Avastin it was detected higher on 14th day than on 7th day with s.s. (p=0.047), indicating a continuing angiogenetic activity. Parallel and in accordance with VEGF measurements were those of CRP. It was found increased s.s. on 7th day in Avastin group compared with placebo group (p=0.007). Likewise, it was higher with s.s. in control group without Avastin on 14th day than on 7th day (p=0.009). ET-1, which is an ischemic marker, was found higher with s.s. in Avastin group on 14th day than on 7th day (p=0.027). The PAB was found in Avastin group decreased s.s. on 14th day compared with 7th day (p=0.021) indicating a decline in the degree of the oxidative stress. Carbonyl proteins, which are a general biomarker of severe oxidative protein damage, were found increased s.s. in placebo group on 7th day, when compared with both Avastin group on 7th day (p=0.003) and placebo group on 14th day (p=0.009). Likewise, bevacizumab had no influence on abdominal wound healing also, by inspection as well as by neither histopathology nor hydroxyproline levels. In serum the values of CRP were higher s.s. in control group without Avastin on 14th day than on 7th day (p=0.009) and then in Avastin group on 14th day (p=0.002). Also, carbonyl proteins were higher s.s. in Avastin group on 14th day than on 7th day (p=0.023). The rest of the above parameters in serum and those of ET-1 and PAB did not have any s.s. difference. Bevacizumab, when administered intraperitoneally during the operation, had no significant proven effect on colon anastomotic healing in rats. This experimental study has proved, despite the caused transient ischemia and oxidative stress, no significant alterations in collagen synthesis and fibrosis or in bursting pressure, indicating no crucial impairment of wound healing process. Also, it seems that it has no substantial influence on the abdominal wound healing.

Degree

thesis:*
Grantor dc:publisher
Aristotle University Of Thessaloniki (AUTH)
Year dc:date
2011

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Pavlidis, Efstathios
  • Παυλίδης, Ευστάθιος

Subjects

dc:subject × 12

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/25848

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Pavlidis, Efstathios; Παυλίδης, Ευστάθιος. Η επίδραση της bevacizumab στην επούλωση των αναστομώσεων του παχέος εντέρου: πειραματική μελέτη σε επίμυες. Aristotle University Of Thessaloniki (AUTH), 2011. http://hdl.handle.net/10442/hedi/25848